FLAM
KYMR icon

First Light Asset Management’s Kymera Therapeutics KYMR Stock Holding History

First Light Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-383,310
Closed -$15.4M – 40
2024
Q4 		$15.4M Sell
383,310
-23,038
-6% -$1.04M 1.48% 21
2024
Q3 		$19.2M Buy
+406,348
New +$17.9M 1.6% 27

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

First Light Asset Management's KYMR Position: Q1 2025 in Review

First Light Asset Management sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 383,310 shares — an estimated $15.4M sold.

First Light Asset Management first reported a position in KYMR in Q3 2024 and held it in 2 quarters. The position peaked at $19.2M in Q3 2024. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

  • First Light Asset Management reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • First Light Asset Management sold 383,310 Kymera Therapeutics shares in Q1 2025, an estimated $15.4M.
  • First Light Asset Management first reported a position in Kymera Therapeutics in Q3 2024 and held it in 2 quarters.
  • First Light Asset Management's Kymera Therapeutics position peaked at $19.2M in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on First Light Asset Management's 13F filing for Q1 2025, filed 15 May 2025.